NP90323(c) Botulinum Toxin Type A Medicines (Xeomin®)

Concepts

• edinburgh
• pharmaceutical products
• botulinum toxin type a
• botulinum toxin type a medicines(xeomin®
• botulinum toxin type a medicines
• xeomin®
• botulinum toxin type a injection 50-unit vial/ botulinum toxin type a injection 100-unit vial/ botulinum toxin type a injection 200-unit vial
• (xeomin®
• medicines(xeomin
• np90323(c

Location

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014

Description

Supply of Botulinum Toxin Type A Medicines(Xeomin®) to NHS Scotland: NP90323(c): Botulinum Toxin Type A Injection 50-unit vial/ Botulinum Toxin Type A Injection 100-unit vial/ Botulinum Toxin Type A Injection 200-unit vial (Xeomin®)

Total Quantity or Scope

The Framework Agreement is for the supply of Botulinum Toxin Type A (Xeomin®) to NHS Scotland. The Authority has awarded this framework as a Single supplier framework agreement to one (1) Framework Participant.

Award Detail

Award Criteria

CPV Codes

• 33600000 - Pharmaceutical products

Indicators

• Award on basis of price.

Legal Justification

The medicine to be awarded to the framework agreement is protected by exclusive rights, including intellectual property rights, in line with Regulation 33(1)(b)(iii) of the Public Contracts (Scotland) Regulations 2015.

Other Information

The estimated value(s) of the Framework Agreement referred to in Sections II.1.7 and V.2.4 cover(s) the thirty-six (36) month contract duration and the twelve (12) month extension period of the Framework Agreement. (SC Ref:749562)